Are you over 18 and want to see adult content?
More Annotations
A complete backup of breedingbetterdogs.com
Are you over 18 and want to see adult content?
A complete backup of soignez-vous.com
Are you over 18 and want to see adult content?
A complete backup of ilissoedizioni.it
Are you over 18 and want to see adult content?
A complete backup of tuviphongthuytamlinh.com
Are you over 18 and want to see adult content?
A complete backup of perspectivia.net
Are you over 18 and want to see adult content?
A complete backup of fibreculturejournal.org
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of programminglibrarian.org
Are you over 18 and want to see adult content?
A complete backup of retailinsiders.nl
Are you over 18 and want to see adult content?
Text
permeability
ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
CANNABIS ARTERITIS
Following the November elections, there are now 29 states and the District of Columbia that have legalized marijuana (aka cannabis) for medical use. Of these, eight states and the District of Columbia have also approved laws legalizing marijuana for recreational use. Regardless of the stated benefits associated with marijuana use, there are potential health risks. HIGH MORTALITY WITH ANCA ASSOCIATED VASCULITIS Mortality remains high in patients with the types of vasculitis that are associated with the presence of antineutrophil cytoplasmic antibodies (ANCA), a meta-analysis in Annals of the Rheumatic Diseases determined. Compared with the general population, patients with ANCA-associated vasculitis had a 2.7-fold increased mortality, with a meta-standardized mortality ratio (SMR) of 2.71 (95% CI 2 NOVEL BIOLOGIC PROMISING IN MID-STAGE SCLERODERMA TRIAL The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean change from baseline on the modified Rodnan skin score was -4.76 for patients randomized to romilkimab compared with -2.45 for those given placebo, for a mean difference of -2.31 (-4.32 to -0.31 WARFARIN SUPERIOR TO XARELTO IN ANTIPHOSPHOLIPID SYNDROME A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the SHOULD IMMUNOGLOBULINS BE MONITORED WITH RITUXIMAB USE Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients. ALLOPURINOL RISKY IN ASIAN POPULATION The go-to drug to treat hyperuricemia and gout, allopurinol, put patients at risk for developing hypersensitivity when American College of Rheumatology guidelines weren't followed, a large database study found. In Taiwan, from 2005 to 2011, the rates of patients initiating allopurinol and developing hypersensitivity increased by 4.68 per 1,000 patients, as did the rates of hospitalization, 2 HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your DSB: MANAGING METHOTREXATE TOXICITY Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA. In rheumatology, MTX has been the first-line drug against which all other agents are judged. It is the preferred agent in early and late disease and has been the anchor drug to all NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
CANNABIS ARTERITIS
Following the November elections, there are now 29 states and the District of Columbia that have legalized marijuana (aka cannabis) for medical use. Of these, eight states and the District of Columbia have also approved laws legalizing marijuana for recreational use. Regardless of the stated benefits associated with marijuana use, there are potential health risks. HIGH MORTALITY WITH ANCA ASSOCIATED VASCULITIS Mortality remains high in patients with the types of vasculitis that are associated with the presence of antineutrophil cytoplasmic antibodies (ANCA), a meta-analysis in Annals of the Rheumatic Diseases determined. Compared with the general population, patients with ANCA-associated vasculitis had a 2.7-fold increased mortality, with a meta-standardized mortality ratio (SMR) of 2.71 (95% CI 2 NOVEL BIOLOGIC PROMISING IN MID-STAGE SCLERODERMA TRIAL The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean change from baseline on the modified Rodnan skin score was -4.76 for patients randomized to romilkimab compared with -2.45 for those given placebo, for a mean difference of -2.31 (-4.32 to -0.31 WARFARIN SUPERIOR TO XARELTO IN ANTIPHOSPHOLIPID SYNDROME A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the SHOULD IMMUNOGLOBULINS BE MONITORED WITH RITUXIMAB USE Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients. ALLOPURINOL RISKY IN ASIAN POPULATION The go-to drug to treat hyperuricemia and gout, allopurinol, put patients at risk for developing hypersensitivity when American College of Rheumatology guidelines weren't followed, a large database study found. In Taiwan, from 2005 to 2011, the rates of patients initiating allopurinol and developing hypersensitivity increased by 4.68 per 1,000 patients, as did the rates of hospitalization, 2NEWS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in yourRHEUMNOW PODCAST
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.VIDEOS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28%RHEUMNOW
The second day of EULAR 2021 took a big leap in online content. #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by ourRheumNow faculty.
RULES FOR DRUG CESSATION WITH INFECTION Everyone gets their education about drug-related infection risk from television ads. Rheumatologists should know what the real risks are and educate their patients that they have a higher than normal rate of nonserious infections. But the infection risk is way more related to inflammation than any specific drug risk. ACR/AAHKS GUIDELINES ON PERIOPERATIVE MANAGEMENT The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total jointreplacement.
FDA APPROVES MEPOLIZUMAB FOR CHURG-STRAUSS (EGPA) The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of10.7 to 14
ABATACEPT USE DURING SURGERY The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs. The 2016 Annual ACR meeting saw new guidelines on perioperative management and a number of abstracts suggesting the safety and advantages of continued DMARD and biologic use in those undergoing major surgery. SWOLLEN JOINTS ASSOCIATED WITH ULTRASOUND SYNOVITIS IN PSA Ultrasonography has been added to the rheumatologist’s toolbox in recent years as a sensitive imaging modality in assessment of inflammatory arthritis but its relationship with tender or swollen joints is not quite clear. A large study of early, DMARD naive PsA patients shows that swollen joints, but not tender joints are associated with ultrasound power doppler synovitis. HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in yourRHEUMNOW PODCAST
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
DSB: MANAGING METHOTREXATE TOXICITY Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA. In rheumatology, MTX has been the first-line drug against which all other agents are judged. It is the preferred agent in early and late disease and has been the anchor drug to all NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
FDA APPROVES MEPOLIZUMAB FOR CHURG-STRAUSS (EGPA) The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of10.7 to 14
PREGNANCY OUTCOMES WITH CERTOLIZUMAB: DR. KATHRYN DAO Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. HIGH MORTALITY WITH ANCA ASSOCIATED VASCULITIS Mortality remains high in patients with the types of vasculitis that are associated with the presence of antineutrophil cytoplasmic antibodies (ANCA), a meta-analysis in Annals of the Rheumatic Diseases determined. Compared with the general population, patients with ANCA-associated vasculitis had a 2.7-fold increased mortality, with a meta-standardized mortality ratio (SMR) of 2.71 (95% CI 2 ABATACEPT USE DURING SURGERY Abatacept Use During Surgery. Save. The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs. The 2016 Annual ACR meeting saw new guidelines on perioperative management and a number of abstracts suggesting the safety and advantages of continued VIDEO: PERSONALIZATION OF PSA TREATMENT: DR. ROBERT CHAO Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your EULAR 2021 – DAY 4 REPORT Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. Mavrilimumab in COVID-19: LB0001– Mavrilimumab, (MAV) a human anti GM-CSF receptor α antibody, was shown at ACR 2020 to be effective in treating giant cell arteritis. At EULAR, mavrilimumab was tested in patients with severe, hospitalized COVID-19RHEUMNOW PODCAST
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
VIDEO: IFN SCORES PREDICT RESISTANCE TO SKIN DISEASE Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting. VIDEO: DID I FORGET SOMETHING? DR. JONATHAN KAY Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: TREATMENT OPTIONS FOR PSA PATIENTS: DR. PAUL Video: Treatment Options for PsA Patients: Dr. Paul Studenic Dr. Paul Studenic reviews highlights from three PsA abstracts - abstract op0227, abstract op0229, and abstract op0233 - presented at the virtual #EULAR2021 meeting. VIDEO: THE PSA SPA PARADOX OF CHOICE DR. RACHEL TATE Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at #EULAR2021 DAY 4 REPORT LOTS OF PRESENTATIONS ON THE LAST #EULAR2021 Day 4 Report Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. VIDEO: DID I FORGET SOMETHING? DR. JONATHAN KAY Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: COMBINATION DMARD FOR LUPUS NEPHRITIS: DR. KATHRYN Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: RA AND CANCER: MYTH OR REALITY? DR. JONATHAN KAY Video: RA and Cancer: Myth or Reality? Dr. Jonathan Kay ( @RheumKay ) Dr. Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract OP0187, presented at #EULAR2021. LESSONS LEARNED IN SLE An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways altered in these patients included CD4 differentiation, JAK Stat, interferon and abnormalities in dendritic cells and macrophages. This can help to understand the heterogeneity of the disease, differential responses to PSORIATIC ARTHRITIS MORTALITY & MORBIDITIES BY DR. PAUL Psoriatic arthritis mortality & morbidities by Dr. Paul Studenic #EULAR2021 PsA is a chronic condition with manifol PREGNANCY OUTCOMES WITH CERTOLIZUMAB: DR. KATHRYN DAO Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: THE FUTURE OF TREATMENT OF RA-ILD: DR. DAVID LIEW Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: WHAT KIND OF DIET SHOULD YOU BE ON? WITH DR. ROBERT Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: PREVALENCE OF LONG TERM HCQ IN RETINAL TOXICITY: DR Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 ) Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021. RT @AURELIERHEUMO: CURIOUS TO FIND OUT THE ANSWER?HTTPS Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your EULAR 2021 – DAY 4 REPORT Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. Mavrilimumab in COVID-19: LB0001– Mavrilimumab, (MAV) a human anti GM-CSF receptor α antibody, was shown at ACR 2020 to be effective in treating giant cell arteritis. At EULAR, mavrilimumab was tested in patients with severe, hospitalized COVID-19RHEUMNOW PODCAST
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
VIDEO: IFN SCORES PREDICT RESISTANCE TO SKIN DISEASE Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting. VIDEO: DID I FORGET SOMETHING? DR. JONATHAN KAY Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: TREATMENT OPTIONS FOR PSA PATIENTS: DR. PAUL Video: Treatment Options for PsA Patients: Dr. Paul Studenic Dr. Paul Studenic reviews highlights from three PsA abstracts - abstract op0227, abstract op0229, and abstract op0233 - presented at the virtual #EULAR2021 meeting. HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your EULAR 2021 – DAY 4 REPORT Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. Mavrilimumab in COVID-19: LB0001– Mavrilimumab, (MAV) a human anti GM-CSF receptor α antibody, was shown at ACR 2020 to be effective in treating giant cell arteritis. At EULAR, mavrilimumab was tested in patients with severe, hospitalized COVID-19RHEUMNOW PODCAST
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
VIDEO: IFN SCORES PREDICT RESISTANCE TO SKIN DISEASE Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting. VIDEO: DID I FORGET SOMETHING? DR. JONATHAN KAY Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: TREATMENT OPTIONS FOR PSA PATIENTS: DR. PAUL Video: Treatment Options for PsA Patients: Dr. Paul Studenic Dr. Paul Studenic reviews highlights from three PsA abstracts - abstract op0227, abstract op0229, and abstract op0233 - presented at the virtual #EULAR2021 meeting.VIDEOS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your EULAR 2021 – DAY 4 REPORT Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. Mavrilimumab in COVID-19: LB0001– Mavrilimumab, (MAV) a human anti GM-CSF receptor α antibody, was shown at ACR 2020 to be effective in treating giant cell arteritis. At EULAR, mavrilimumab was tested in patients with severe, hospitalized COVID-19 LESSONS LEARNED IN SLE An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways altered in these patients included CD4 differentiation, JAK Stat, interferon and abnormalities in dendritic cells and macrophages. This can help to understand the heterogeneity of the disease, differential responses to DON'T KILL THE KRILL: DR. KATHRYN DAO Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: IFN SCORES PREDICT RESISTANCE TO SKIN DISEASE Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting. PSORIATIC ARTHRITIS MORTALITY & MORBIDITIES BY DR. PAUL Psoriatic arthritis mortality & morbidities by Dr. Paul Studenic #EULAR2021 PsA is a chronic condition with manifol DO B-CELL TARGETED THERAPIES STILL HAVE A PLACE FOR THE Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. VIDEO: THE PSA SPA PARADOX OF CHOICE DR. RACHEL TATE Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at PROMISING OPTIONS TO TREAT MUCOCUTANEOUS DISEASE IN SLE # Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. #EULAR2021 DAY 4 REPORT LOTS OF PRESENTATIONS ON THE LAST #EULAR2021 Day 4 Report Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your DSB: MANAGING METHOTREXATE TOXICITY Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA. In rheumatology, MTX has been the first-line drug against which all other agents are judged. It is the preferred agent in early and late disease and has been the anchor drug to all ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28%CANNABIS ARTERITIS
Following the November elections, there are now 29 states and the District of Columbia that have legalized marijuana (aka cannabis) for medical use. Of these, eight states and the District of Columbia have also approved laws legalizing marijuana for recreational use. Regardless of the stated benefits associated with marijuana use, there are potential health risks. WARFARIN SUPERIOR TO XARELTO IN ANTIPHOSPHOLIPID SYNDROME A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the RULES FOR DRUG CESSATION WITH INFECTION Everyone gets their education about drug-related infection risk from television ads. Rheumatologists should know what the real risks are and educate their patients that they have a higher than normal rate of nonserious infections. But the infection risk is way more related to inflammation than any specific drug risk. ABATACEPT USE DURING SURGERY Abatacept Use During Surgery. Save. The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs. The 2016 Annual ACR meeting saw new guidelines on perioperative management and a number of abstracts suggesting the safety and advantages of continued SHOULD IMMUNOGLOBULINS BE MONITORED WITH RITUXIMAB USE Nov 08, 2018 3:00 am. Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients. Published analyses of RTX rheumatoid arthritisclinical
HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your DSB: MANAGING METHOTREXATE TOXICITY Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA. In rheumatology, MTX has been the first-line drug against which all other agents are judged. It is the preferred agent in early and late disease and has been the anchor drug to all ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28%VIDEOS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your EULAR 2021 – DAY 4 REPORT Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. Mavrilimumab in COVID-19: LB0001– Mavrilimumab, (MAV) a human anti GM-CSF receptor α antibody, was shown at ACR 2020 to be effective in treating giant cell arteritis. At EULAR, mavrilimumab was tested in patients with severe, hospitalized COVID-19LUPUS-EULAR 2021
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for ournewsletter.
RHEUMNOW LIVE 2021 NOW AVAILABLE FOR ALL RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR). RNL has finished its 3rd year as a hybrid meeting, with the live meeting streamed to hundreds at home, who are watching and interacting on the same content viewed by those in attendance in Fort Worth.PODCAST | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for ournewsletter.
EULAR 2021 - DAY 3 REPORT Here are a few notable presentations from Day 3. BEAT- LUPUS Trial: OP0129 – I would consider this a pilot trial as it only included 52 patients with active SLE, but the gist was that active SLE patients were first treated with rituximab (RTX: 2 infusions) followed by randomization to either placebo or belimumab IV every 4-8 weeks after their 1st dose of rituximab. CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28% TNF INHIBITION AND HEART FAILURE Here are the facts and data necessary to make a cogent decision to use or avoid TNFi. The product label for marketed TNF inhibitors state, under warnings, that congestive heart failure, “worsening or new onset”, may occur. It also says that in some studies, a higher rate of serious CHF-related adverse reactions was observed with TNFi use ACR/AAHKS GUIDELINES ON PERIOPERATIVE MANAGEMENT The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total jointreplacement.
SHOULD IMMUNOGLOBULINS BE MONITORED WITH RITUXIMAB USE Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients. HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in yourVIDEOS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your DSB: MANAGING METHOTREXATE TOXICITY Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA. In rheumatology, MTX has been the first-line drug against which all other agents are judged. It is the preferred agent in early and late disease and has been the anchor drug to all ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28% WARFARIN SUPERIOR TO XARELTO IN ANTIPHOSPHOLIPID SYNDROME A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains theCANNABIS ARTERITIS
Following the November elections, there are now 29 states and the District of Columbia that have legalized marijuana (aka cannabis) for medical use. Of these, eight states and the District of Columbia have also approved laws legalizing marijuana for recreational use. Regardless of the stated benefits associated with marijuana use, there are potential health risks. ABATACEPT USE DURING SURGERY Abatacept Use During Surgery. Save. The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs. The 2016 Annual ACR meeting saw new guidelines on perioperative management and a number of abstracts suggesting the safety and advantages of continued ALLOPURINOL RISKY IN ASIAN POPULATION The go-to drug to treat hyperuricemia and gout, allopurinol, put patients at risk for developing hypersensitivity when American College of Rheumatology guidelines weren't followed, a large database study found. In Taiwan, from 2005 to 2011, the rates of patients initiating allopurinol and developing hypersensitivity increased by 4.68 per 1,000 patients, as did the rates of hospitalization, 2 HOME | RHEUMNOWNEWSVIDEOSPODCASTDAILY DOWNLOADSBLOG Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in yourVIDEOS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your DSB: MANAGING METHOTREXATE TOXICITY Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA. In rheumatology, MTX has been the first-line drug against which all other agents are judged. It is the preferred agent in early and late disease and has been the anchor drug to all ALCOHOL AND METHOTREXATE What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX? Many rheumatologists have crafted alcohol and methotrexate policies to protect patients and reduce the risk associated with coadministration of these potentialhepatotoxins.
NSAIDS AND THE RISK OF INFLAMMATORY BOWEL DISEASE Your patient with Crohn’s or ulcerative colitis has a musculoskeletal problem that needs treatment. You consider a nonsteroidal anti-inflammatory drug, but are reminded that “NSAIDs are to be avoided as these drugs will worsen inflammatory bowel disease (IBD)”. Aside from their effects on prostaglandins, NSAIDs have been postulated to incite damage by increasing mucosalpermeability
CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28% WARFARIN SUPERIOR TO XARELTO IN ANTIPHOSPHOLIPID SYNDROME A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains theCANNABIS ARTERITIS
Following the November elections, there are now 29 states and the District of Columbia that have legalized marijuana (aka cannabis) for medical use. Of these, eight states and the District of Columbia have also approved laws legalizing marijuana for recreational use. Regardless of the stated benefits associated with marijuana use, there are potential health risks. ABATACEPT USE DURING SURGERY Abatacept Use During Surgery. Save. The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs. The 2016 Annual ACR meeting saw new guidelines on perioperative management and a number of abstracts suggesting the safety and advantages of continued ALLOPURINOL RISKY IN ASIAN POPULATION The go-to drug to treat hyperuricemia and gout, allopurinol, put patients at risk for developing hypersensitivity when American College of Rheumatology guidelines weren't followed, a large database study found. In Taiwan, from 2005 to 2011, the rates of patients initiating allopurinol and developing hypersensitivity increased by 4.68 per 1,000 patients, as did the rates of hospitalization, 2VIDEOS | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in yourPODCAST | RHEUMNOW
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for ournewsletter.
MEET OUR TEAM
A valid email address. All emails from the system will be sent to this address. The email address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by email. DOWNLOADS AND RESOURCES Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in yourLUPUS-EULAR 2021
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for ournewsletter.
PREGNANCY OUTCOMES WITH CERTOLIZUMAB: DR. KATHRYN DAO Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. CAUSE OF DEATH IN ANKYLOSING SPONDYLITIS A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology. They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009). The mortality rate of AS remained stable over time. The most frequent causes of death in AS patients were death certificates were CV disease (46%-28% MANAGEMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells. HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure. While HLH is rarely genetic (primary) and seen in children; the more frequent secondary (acquired) form is seen adults. IS METHOTREXATE NECESSARY WITH TOFACITINIB? Jun 18, 2019 5:39 pm. Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid. After 24 weeks of treatment, patients treated with tofacitinib SEVERITY ASSOCIATED WITH EROSIVE HAND OSTEOARTHRITIS Erosive hand osteoarthritis (EHOA) was studied as part of the Osteoarthritis Initiative, and shown to increase with advanced age and female sex, with developmental findings to suggest that EHOA as a disorder of skeletal frailty. The Osteoarthritis Initiative is a longitudinal study of OA patients followed clinical and with radiographs from baseline and 48‐months. Skip to main contentUSER ACCOUNT MENU
* Log in
* Register
HEADER MENU
* News
* Videos
* Podcast
* Daily Downloads
* Blog
* More
CATEGORIES
* Blogs
* News
* Podcast
* Rx Updates
* Social
* Daily Downloads
* Videos
* Conferences
* Coronavirus
* Popular
TOPICS
* Anti-Rheumatic Rx
* AS/Spondyloarthritis* Biologics
* Drug Safety
* Education/ACR/EULAR* Fibromyalgia/Pain
* Gout
* Lupus
* Other
* Psoriatic arthritis * Rheumatoid Arthritis* TNF inhibitor
__ Search
__
RECENT NEWS
*
EULAR 2021 – Day 2 Report__ Save
Jack Cush, MD
Jun 04, 2021
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlightsfrom Day 2.
Read Article
Looking for RA specific coverage? We've got you covered. #EULAR2021 https://t.co/eXD5UK2RRp https://t.co/RI3aMW2E2gLinks:
* __https://bit.ly/3pl2dXY Dr. John Cush @RheumNow ( __ ViewTweet )
Jun 05, 2021
SPIRIT-P1&P2: IXE is effective in⬇️axial symptoms & improving QoL in active PsA pts with axial involvement. Abstract #POS1045 #EULAR2021 @RheumNow https://t.co/GC78Lmp9cH https://t.co/WfaUqIRrY6Links:
* __http://ow.ly/IzO350F3G7I Dr. Rachel Tate @uptoTate ( __ ViewTweet )
Jun 05, 2021
A single dose of LORECIVIVINT IA (Wnt pathway modulator) in Phase 3 study in knee OA: mild improvement of WOMAC pain -8.16 P=0.032 and function -9.47 P=0.015 at 6 and 12months with no particular safety signal. #POS0278 #EULAR2021 @RheumNow https://t.co/5qQE6MPjnU Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 05, 2021
#POS1069 Quite promising results of the use of an easy to use quick quantitative CRP assay to be included in the DAPSA to facilitate immediate decision making. @ProftDr In 98% identical disease activity classification than with #DAPSA #EULAR2021 @RheumNow https://t.co/Rt8fKvKBC4 Paul Studenic @Stiddyo ( __ ViewTweet )
Jun 05, 2021
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLWLinks:
* __http://ow.ly/zwsd50F3v4n Dr. Rachel Tate @uptoTate ( __ ViewTweet )
Jun 05, 2021
How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/z8c8moIQCa #EULAR2021Links:
* __https://bit.ly/3vO6Ig9 Dr. John Cush @RheumNow ( __ ViewTweet )
Jun 05, 2021
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhiLinks:
* __http://ow.ly/Q4wp50F3uTN Dr. Rachel Tate @uptoTate ( __ ViewTweet )
Jun 05, 2021
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal. #LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 05, 2021
We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O Md Yuzaiful Md Yusof @Yuz6Yusof( __ View Tweet
)
Jun 05, 2021
Even when we go outright looking for COVID vaccine-related problems in rheum disease patients, we really don't find much. Get your rheumatology patients vaccinated! reassuring from @eular_org COVAX registry, thanks to all involved! @pedrommcmachado LB0002 #EULAR2021 @RheumNow https://t.co/mIBeglQ5KS David Liew @drdavidliew ( __ ViewTweet )
Jun 05, 2021
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHgLinks:
* __https://bit.ly/3fS5SJX Dr. John Cush @RheumNow ( __ ViewTweet )
Jun 05, 2021
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting. https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZgLinks:
* __https://bit.ly/3g8wMfj Dr. John Cush @RheumNow ( __ ViewTweet )
Jun 05, 2021
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty. Dr. John Cush @RheumNow ( __ ViewTweet )
Jun 05, 2021
DANBIO + Swedish register SGR linked to national birth registers (matched 1:10): RA-pregnancies: higher preterm birth (OR 1.92, 95CI 1.56-2.35) and small gestational age (OR 1.93, 95CI 1.45-2.57). Association strengthened by high disease activity. #OP0210 @Rheumnow #EULAR2021 https://t.co/Fjm0uxCPgC Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 04, 2021
KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal. #OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 04, 2021
What is the impact of RA on fertility in men: #OP0211 and #OP0212 @Rheumnow #EULAR2021 Aurelie Najm @AurelieRheumo ( __View Tweet
)
Jun 04, 2021
COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI. #OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 04, 2021
Retrospective RA cohort study: overall risk of dementia ⬆️ in RA (HR 1.38; 95%CI 1.04-1.83) BUT 10-year cumulative incidence of dementia ⬇️: 12.7% in 1980s 7.2% in 1990s 2000s 6.2% Risk no longer significantly ⬆️ for patients w/ RA onset in 2000s! @RheumNow #EULAR2021 #OP0216 https://t.co/TVRTTJjvno Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 04, 2021
Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 04, 2021
COVID-19 Global Rheum Alliance Registry: prediction of ARDS by machine learning algorithm in a model using 42 variables including: demographics, rheumatic D, meds and comorb with Sens 0.81, Spe 0.49, AUC 075. Interesting model for close monitoring #OP0288 @Rheumnow #EULAR2021 https://t.co/9YY0jzDx59 Aurelie Najm @AurelieRheumo( __ View Tweet
)
Jun 04, 2021
More News
FEATURED VIDEO
DIFFICULT TO TREAT RA: DR. JANET POPE PSA AND MORTALITY: DR. ROBERT CHAO RA AND DEMENTIA: TRYING TO FORGET THE PROBLEM? DR. DAVID LIEW NR-AXSPA VS AXSPA — DOES IT MATTER? DR. MERAL EL RAMAHI USING VITAMIN D IN RA: DR. JANET POPE CAN FOCUS SCORE PREDICT RISK OF LYMPHOMA IN SJOGREN'S PATIENTS? DR.ERIC DEIN
FROM THE BLOG
Rebuttals
__ Save
Kathryn H. Dao, M.D.Mar 15, 2021
Since the COVID vaccine rollout, more people have been eligible to receive the vaccine. However, not everyone chooses to get one. I have heard many reasons (aka excuses) from my patients who are vaccinehesitant.
Most come from people who are highly intelligent, and claimed that they will receive the vaccine but not yet. While I am not trying to force people to get vaccinated, I wanted to hear their side of the story and also ask that they hear mine.Read Post
RECENT PODCASTS
Your browser does not support the audio element.*
RheumNow Podcast - EULAR 2021 & EULAR-IQJun 04, 2021
*
EULAR 2021 - Day2d
Jun 04, 2021
*
EULAR 2021 - Day2c
Jun 04, 2021
*
EULAR 2021 - Day2b
Jun 04, 2021
*
EULAR 2021 - Day2a
Jun 04, 2021
THERAPEUTIC UPDATE
Upadacitinib’s Long Term Efficacy and Safety__ Save
Sponsored by AbbVie Medical AffairsJun 01, 2021
Explore upadacitinib’s long-term efficacy through 3 years in the SELECT-COMPARE trial and dig into data for the integrated safety analysis across 6 phase 3 studies with up to ~4.5 years of exposure.Read Post
DAILY DOWNLOAD
Difficult RA Defined__ Save
__ Download See More ResourcesPlay Video
Play
Mute
Current Time 0:00
/
Duration Time 0:00
Loaded: 0%
Progress: 0%
Stream TypeLIVE
Remaining Time -0:00Playback Rate
1
* Chapters
Chapters
* descriptions off, selectedDescriptions
* subtitles off, selectedSubtitles
* captions settings, opens captions settings dialog * captions off, selectedCaptions
Audio TrackFullscreen This is a modal window. Caption Settings Dialog Beginning of dialog window. Escape will cancel and close the window. TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque Font Size50%75%100%125%150%175%200%300%400% Text Edge StyleNoneRaisedDepressedUniformDropshadow Font FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsDefaultsDone
*
Now Playing
*
Now Playing
*
Now Playing
*
Now Playing
*
Now Playing
Close
OTHER LINKS
* Our Team
* Privacy Policy
* Rheumaknowledgy.com* StillNow.com
DO YOU GET OUR EMAIL NEWSLETTER? You must have JavaScript enabled to use this form. Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:newsletter.
* __ info@rheumnow.com Copyright 2021 All Rights Reserved.×Close
LOGIN/REGISTER
You must have JavaScript enabled to use this form.Email Address
Password
Remember me
* Create new account * Reset your password New User? Register HereForgot password?
You must have JavaScript enabled to use this form.Email address
A valid email address. All emails from the system will be sent to this address. The email address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by email.Full Name
Profile Photo
Focal point
Specify the focus of this image in the form "leftoffset,topoffset" where offsets are in percents. Ex: 25,75 Your photo to be displayed with comments. After uploading your image, move the crosshair to the area of the image that should be the "focus"area.
Reader Type Select an optionMedia/PressMedical Society/OrganizationOther Healthcare ProfessionalOther PhysicianPatient or Concerned IndividualPharmaceutical Industry or Biotech IndividualPharmacistPhysician Assistant, Nurse Practitioner, Rheumatology NursePrimary PhysicianRheumatologistTrainee (Fellow,Resident, Student)
Country
Zip Code
Leave this field blankLogin
×
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0